Skip to main content
Fig. 2 | BMC Pediatrics

Fig. 2

From: Evaluating the effect of recombinant human growth hormone treatment on sleep-related breathing disorders in toddlers with Prader–Willi syndrome: a one-year retrospective cohort study

Fig. 2

The anthropometric data and IGF-1 z-score in the non-rhGH group and rhGH group after 52 weeks treatment. No significant difference was identified for the weight (A) and height (B) between rhGH treatment and non-rhGH treatment group. The value of W/H z-score in the non-rhGH treatment group was significantly higher than the rhGH group (C). The level of IGF-1 z-score in the non-rhGH was significantly lower than the rhGH group (D). NS.: no significance, *: p-value < 0.05, ***: p-value < 0.001

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us